Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$2,650 Mln
P/E Ratio
--
P/B Ratio
2.95
Industry P/E
--
Debt to Equity
0
ROE
-0.18 %
ROCE
-17.86 %
Div. Yield
0 %
Book Value
8.08
EPS
-1.01
CFO
$-270.79 Mln
EBITDA
$-346.12 Mln
Net Profit
$-375.21 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
| -40.51 | -22.50 | -26.47 | -64.77 | 105.47 | 34.01 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
| 114.87 | 97.98 | 104.35 | -18.29 | -29.80 | 4.84 | 87.77 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype... selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Address: 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 Read more
President, CEO & Director
Dr. Brian Lian Ph.D.
President, CEO & Director
Dr. Brian Lian Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Viking Therapeutics Inc (VKTX) stood at $ 908 Mln as on 31-Dec-24
The share price of Viking Therapeutics Inc (VKTX) is $23.94 (NASDAQ) as of 17-Apr-2025 16:22 EDT. Viking Therapeutics Inc (VKTX) has given a return of 105.47% in the last 3 years.
Viking Therapeutics Inc (VKTX) has a market capitalisation of $ 2,650 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Viking Therapeutics Inc (VKTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Viking Therapeutics Inc (VKTX) and enter the required number of quantities and click on buy to purchase the shares of Viking Therapeutics Inc (VKTX).
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Address: 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121
The CEO & director of Dr. Brian Lian Ph.D.. is Viking Therapeutics Inc (VKTX), and CFO & Sr. VP is Dr. Brian Lian Ph.D..
There is no promoter pledging in Viking Therapeutics Inc (VKTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Viking Therapeutics Inc. (VKTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-17.9
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Viking Therapeutics Inc (VKTX) was $0 Mln.
$0.34
(
